Marcy Lim, MD
Cardiovascular Disease · Humble, TXNPI 1578671392
Payments from drug & device makers
Across 223 payments — averaging $145.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$26K
- Abbott$2K
- Bard Peripheral Vascular, Inc.$466
- Johnson & Johnson$362
- Novartis$353
- Cvrx, Inc.$260
- plus $3K from 32 others
What the payments were for
- Royalty or licence$25,85780%
- Food & beverage$6,48020%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 3 | $25,912 |
| Abbott | 19 | $1,582 |
| Bard Peripheral Vascular, Inc. | 14 | $466 |
| Johnson & Johnson | 18 | $362 |
| Novartis | 17 | $353 |
| Cvrx, Inc. | 5 | $260 |
| Pfizer | 10 | $258 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 16 | $248 |
| Boston Scientific | 9 | $244 |
| Heartflow, Inc. | 4 | $237 |
| E.r. Squibb & Sons, L.L.C. | 12 | $204 |
| Kestra Medical Technology Services, Inc. | 2 | $201 |
| Amarin Pharma, Inc. | 12 | $197 |
| Impulse Dynamics (USA) Inc. | 9 | $179 |
| Amgen | 9 | $174 |
| Boehringer Ingelheim | 3 | $161 |
| Esperion Therapeutics, Inc. | 9 | $153 |
| Astellas Pharma US Inc | 7 | $153 |
| AstraZeneca | 8 | $123 |
| Alnylam Pharmaceuticals Inc. | 5 | $118 |
| Merck | 6 | $102 |
| Canon Medical Systems USA, Inc. | 3 | $99 |
| Bolton Medical Inc | 1 | $66 |
| Regeneron | 2 | $65 |
| Atricure, Inc. | 1 | $62 |
| Novo Nordisk | 3 | $54 |
| Tactile Systems Technology Inc | 4 | $51 |
| Infobionic, Inc | 1 | $36 |
| Biosense Webster, Inc. | 1 | $34 |
| Regeneron Healthcare Solutions, Inc. | 2 | $33 |
| Resmed Corp | 1 | $25 |
| Cardiovascular Systems Inc. | 1 | $25 |
| Bayer | 1 | $21 |
| Azurity Pharmaceuticals, Inc. | 1 | $19 |
| Althera Pharmaceuticals LLC | 1 | $17 |
| Scpharmaceuticals Inc. | 1 | $17 |
| Kowa Pharmaceuticals America, Inc. | 1 | $13 |
| Arbor Pharmaceuticals, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VenaSeal$25,857
- Ensite Cardiac Mapping System$431
- AVEIR$175
- Confirm Rx$173
- Barostim Neo System$171
- ASSURITY$146
- ENSITE PRECISION$129
- JARDIANCE$118
- FFRct$115
- ENSITE$112
- Assure WCD$109
- VENOVO$100
How this compares
$32,337 in reported general payments places this provider in the 80th percentile of 1,515 cardiovascular disease providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 470 | $571,011 |
| XareltoRivaroxaban | 219 | $269,790 |
| EntrestoSacubitril/Valsartan | 177 | $250,024 |
| Repatha SureclickEvolocumab | 175 | $157,351 |
| Praluent PenAlirocumab | 50 | $47,084 |
| JardianceEmpagliflozin | 36 | $39,563 |
| BrilintaTicagrelor | 33 | $34,806 |
| Repatha SyringeEvolocumab | 29 | $31,606 |
| FarxigaDapagliflozin Propanediol | 16 | $19,463 |
| Metoprolol Succinate | 1,095 | $16,032 |
| Rosuvastatin Calcium | 801 | $14,651 |
| Ezetimibe | 218 | $6,763 |
| Atorvastatin Calcium | 659 | $6,726 |
| Ranolazine ErRanolazine | 62 | $6,414 |
| Losartan Potassium | 549 | $5,857 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $258 | $571,011470 claims |
| Johnson & JohnsonXarelto | $362 | $269,790219 claims |
| NovartisEntresto | $353 | $250,024177 claims |
| AstraZenecaBrilinta, Farxiga | $123 | $54,26949 claims |
| Boehringer IngelheimJardiance | $161 | $39,56336 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,515 cardiovascular disease providers in Texas.
Other cardiovascular disease in Humble
- Raymond LittleHumble$445K
- Ramin Farzaneh-FarDallas$17.1M
- Jeffrey GladdenDallas$15.8M
- Ann NavarDallas$14.5M
- David BrabhamAmarillo$11.5M
- Justin GrodinDallas$6.2M
- Christie BallantyneHouston$4.6M
- Syed NaqviHouston$3.6M
- Faisal WahidMcKinney$3.4M
- James FeldmanHouston$3.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.